metricas
covid
Buscar en
Neurología (English Edition)
Toda la web
Inicio Neurología (English Edition) Intercritical photophobia in the migrainous patient. Proposal for diagnostic cri...
Journal Information
Vol. 38. Issue 6.
Pages 387-390 (July - August 2023)
Visits
1305
Vol. 38. Issue 6.
Pages 387-390 (July - August 2023)
Original article
Full text access
Intercritical photophobia in the migrainous patient. Proposal for diagnostic criteria
Fotofobia intercrítica en el paciente migrañoso. Propuesta de criterios diagnósticos
Visits
1305
F. Ly-Yang
Corresponding author
fernandolyyang@gmail.com

Corresponding author.
, V. Gómez-Calleja, P. Pérez-García, N. González-Gómez, J. Porta-Etessam, E. Santos-Bueso
Unidad de Neurooftalmología, Servicio de Oftalmología, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Abstract
Introduction

Photophobia is a symptom of abnormal light intolerance without pain sensation that requires an anamnesis and an examination to diagnose an underlying etiology.

Basic procedure

This article focuses on 30 clinical cases with isolated intense photophobia and on the review of the literature.

Objective

The purpose of this article is to establish diagnostic criteria for photophobia.

Results

The etiology of photophobia appears to be at the level of the intrinsically photosensitive retinal ganglion cells known as melanopsin cells and at a neurochemical level mediated by calcitonin-related peptide and the pituitary activating peptide cyclase.

Conclusion

The treatment of photophobia could consist of monoclonal antibodies against calcitonin-related peptide and/or pituitary activating peptide cyclase.

Keywords:
Photophobia
Migraine
Headache
Cyclase
Calcitonin
Melanopsin
Resumen
Introducción

La fotofobia es un síntoma de intolerancia anómala a la luz sin sensación de dolor que requiere de una anamnesis y una exploración para el diagnóstico de una etiología subyacente.

Procedimiento básico

El presente artículo se centra en 30 casos clínicos con fotofobia intensa aislada y su revisión de la bibliografía.

Objetivo

El objetivo consiste en establecer unos criterios diagnósticos de la fotofobia.

Resultados

La etiología de la fotofobia parece encontrarse a nivel de las células ganglionares de la retina intrínsecamente fotosensibles, conocidas como las células de la melanopsina, y a un nivel neuroquímico mediado por el péptido relacionado con la calcitonina y el péptido pituitario activador de la ciclasa.

Conclusión

El tratamiento de la fotofobia podría consistir en anticuerpos monoclonales contra los péptidos relacionados con la calcitonina y/o el péptido pituitario activador de la ciclasa.

Palabras clave:
Fotofobia
Migraña
Cefalea
Ciclasa
Calcitonina
Melanopsina
Full Text
Introduction

Photophobia is a painless, anomalous intolerance to light that requires history taking and clinical examination to diagnose the underlying aetiology. Photophobia is usually associated with ophthalmological disease (from anterior segment involvement, such as dry eye syndrome, iritis, and blepharitis, to posterior segment involvement, such as retinal dystrophy and retinitis pigmentosa), neurological disease (from primary headache, with migraine being the most frequent, to traumatic brain injury), psychiatric disorders (depressive disorders and anxiety disorders), or pharmacological treatments (barbiturates, benzodiazepines, or haloperidol).1

This article focuses on photophobia associated with primary headache in the context of migraine. Photophobia presents in up to 80% of patients with migraine, manifesting before or during migraine episodes.1

In this context, photophobia is usually associated with other characteristic symptoms, such as headache, phonophobia, nausea, and vomiting.2

Based on 30 clinical cases and the published literature, we propose a series of diagnostic criteria for intense and isolated photophobia.

Material and methods

We present 30 cases of patients diagnosed with intense, continuous photophobia at the neuro-ophthalmology unit at Hospital Clínico San Carlos and presenting normal neurological and ophthalmological examination results. Only 3 were men. Mean age was 38 years (range, 27-54) (Table 1).

Table 1.

Characteristics of the 30 cases with intense, disabling photophobia.

Sex  Age  Migraine  Aura  Treatment 
Man  38  HFEM  No  Triptans 
Woman  54  LFEM  No  Magnesium 
Woman  36  LFEM  No  Triptans 
Woman  42  LFEM  No  Triptans 
Woman  27  LFEM  No  Melatonin 
Woman  52  LFEM  Yes  Melatonin 
Woman  45  LFEM  No  Topiramate 
Woman  32  HFEM  No  Nebivolol 
Woman  29  HFEM  No  Nebivolol 
Woman  54  HFEM  No  Zonisamide 
Woman  36  HFEM  No  Duloxetine, zonisamide, botulinum toxin 
Woman  38  CM  No  Botulinum toxin, venlafaxine, pregabalin 
Woman  37  CM  No  Pregabalin, lisinopril 
Woman  28  HFEM  No  Triptans 
Woman  35  LFEM  No  Zonisamide 
Woman  45  HFEM  Yes  Zonisamide 
Woman  42  HFEM  Yes  Topiramate 
Woman  34  HFEM  Yes  Duloxetine 
Woman  43  HFEM  No  Melatonin, nebivolol 
Woman  35  HFEM  No  Botulinum toxin, duloxetine 
Woman  34  CM  No  Botulinum toxin 
Woman  42  CM  No  Magnesium, nebivolol 
Woman  36  CM  No  Duloxetine, topiramate 
Man  35  CM  No  Botulinum toxin, melatonin, venlafaxine 
Woman  48  CM  No  Zonisamide, botulinum toxin 
Woman  42  HFEM  No  Candesartan 
Woman  29  HFEM  No  Candesartan 
Woman  38  CM  Yes  Botulinum toxin 
Woman  37  CM  No  Duloxetine, melatonin 
Man  31  HFEM  No  Nebivolol 

CM: chronic migraine; HFEM: high-frequency episodic migraine; LFEM: low-frequency episodic migraine.

The ophthalmological examination included a visual acuity test, biomicroscopy of the anterior pole, intraocular pressure determination, assessment of extrinsic and intrinsic ocular motility, and fundoscopy. Visual field campimetry and optical coherence tomography (OCT) yielded normal results in all cases.

Acute episodes of continuous photophobia that manifested in all patients previously diagnosed with migraine headache (chronic migraine, high- and low-frequency episodic migraine) presented without any prodromal symptom of migraine or any other accompanying symptom. Only 5 patients presented migraine aura in addition to photophobia. No patient manifested any trigger factor or subsequent headache (Table 1).

All patients underwent complementary imaging studies, such as CT and brain MRI; structural disease was not detected in any patient.

Patients with migraine received such treatments as antiepileptic drugs (topiramate, zonisamide, and pregabalin), antidepressants (venlafaxine or duloxetine), beta-blockers (nebivolol), and other drugs (candesartan, magnesium, melatonin, and botulinum toxin) (Table 1).

None of these treatments improved the isolated, disabling photophobia present in all the patients in our series. One of patient had modified all of his everyday habits, covering light sources (windows and balconies), limiting trips outside during daytime, and even adapting light-emitting devices, such as his mobile phone (Figs. 1 and 2).

Figure 1.

A patient’s mobile phone in black and white.

(0.21MB).
Figure 2.

The same patient’s mobile phone (left) compared with a normal phone (right).

(0.16MB).

Having ruled out ophthalmological, neurological, and psychiatric diseases, and diseases caused by pharmacological iatrogenesis, patients were diagnosed with intense, persistent photophobia. The aetiology of photophobia in our patients is functional, in the context of migraine with no subsequent headache.

Discussion

Light sensitivity thresholds are highly variable between patients. Patients with migraine or headache have a reduced threshold and therefore present greater sensitivity. Different wavelengths cause some degree of discomfort. Several studies3 report that such short wavelengths as the colour blue and such long wavelengths as that of red light are particularly unpleasant for patients with migraine.

The decreased sensory threshold in the occipital cortex and the resulting increase in susceptibility to photophobia have been studied using such neuroimaging techniques as functional MRI.4

Retinal phototransduction is performed by intrinsically photosensitive retinal ganglion cells (ipRGC), also known as melanopsin-containing retinal ganglion cells.5 Unlike other ganglion cells, which project axons to the lateral geniculate nucleus, these cells project axons to the suprachiasmatic nucleus6 and to the Edinger-Westphal nucleus to control the pupillary light reflex.1 Furthermore, studies with animal models3,7 have reported that ipRGCs project connections to the pain centres in the thalamus. We may hypothesise that this connection exists in patients with photophobia in the context of migraine.

Because they contain the photosensitive pigment melanopsin, ipRGCs are intrinsically photosensitive, meaning that they may be stimulated by light in the absence of traditional photoreceptors such as cones and rods.6

Studies with animal models describe 3 possible pathways by which ipRGCs transform light stimuli into painful sensations. The first pathway involves activation of the trigeminal nerve, which causes ocular vasodilation and pain activation at the trigeminal level.8 The second pathway consists of a direct connection between ipRGCs and pain centres in the thalamus,3,7 where sensory integration and connections towards the somatosensory cortex take place. The third proposed pathway does not include the optic nerve,9 as studies with animal models have shown direct phototransduction to the trigeminal system after section of the optic nerve.

At the trigeminovascular level, 2 neuropeptides modulate pain transmission in patients with migraine: the calcitonin gene–related peptide (CGRP) and the pituitary adenylate cyclase–activating polypeptide (PACAP). Both are vasodilators and pain triggers.10,11 Animals with mutations in the CGRP receptor showed light-aversive behaviour after administration of CGRP, whereas those lacking PACAP developed no light aversion.12 Both neuropeptides may be the cause of the unique characteristics present in migraineurs and absent in controls, which may lead to photophobia.13

Taking into account the pathophysiology of photophobia at the anatomical level, according to functional neuroimaging studies of the occipital cortex, at the neurophysiological level, analysing the melanopsin-containing retinal ganglion cells, and at the neurochemical level, studying the peptides of the trigeminovascular system, we may establish a series of diagnostic criteria for isolated photophobia. Santos-Ly-Porta diagnostic criteria:

  • Duration of more than 3 months

  • Continuous photophobia lasting longer than 24 hours

  • Meets criteria for episodic migraine

  • Isolated photophobia without aura

  • Not explained by another medical aetiology (medication, psychiatric disorder, etc).

Finally, it is important to differentiate eye involvement from photophobia as a symptom of the visual aura preceding migraine. Photophobia symptoms involve light-related discomfort with unaltered vision; at the neurochemical level, CGRP and PACAP alterations are observed. On the other hand, visual aura manifests as vision loss that depends on the type of aura, and is associated with glutamate alterations.

In conclusion, photophobia is considered an isolated symptom of migraine of unknown prevalence whose recognition by neurologists and ophthalmologists is essential to the correct diagnosis and management of these patients. In our series, the majority of patients were young women. The possible treatment of intense, isolated photophobia may be based on monoclonal antibodies against the CGRP and PACAP peptides.

Conflicts of interest

The authors have no conflicts of interest to declare.

References
[1]
A. Albilali, E. Dilli.
Photophobia: when light hurts, a review.
Curr Neurol Neurosci Rep, 18 (2018), pp. 62
[2]
L. Kelman.
Validation of the classification of migraine without aura (HIS A1.1) proposed in ICHD-2.
Headache, 45 (2005), pp. 1339-1344
[3]
A. Main, I. Vlachonikolis, A. Dowson.
The wavelength of light causing photophobia in migraine and tension-type headache between attacks.
Headache, 3 (2000), pp. 194-199
[4]
A. Russo, M. Silvestro, G. Tesdechi, A. Tessitore.
Physiophathology of migraine: what have we learned from functional imaging?.
Curr Neurol Neurosci Rep, 17 (2017), pp. 95
[5]
S. Hattar, H. Liao, M. Takao, D. Berson, K. Yau.
Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity.
Science, 295 (2002), pp. 1065-1070
[6]
D. Berson, F. Dunn, M. Takao.
Phototransduction by retinal ganglion cells that set the circadian clock.
Science, 295 (2002), pp. 1070-1073
[7]
R. Noseda, L. Constandil, L. Bourgeais, M. Chalus, L. Villanueva.
Changes of meningeal excitability mediated by corticotrigeminal networks: a link for the endogenous modulation of migraine pain.
J Neurosci, 30 (2010), pp. 14420-14429
[8]
K. Okamoto, R. Thompson, A. Tashiro, Z. Chang, D. Bereiter.
Bright light produces Fos-positive neurons in caudal trigeminal brainstem.
Neuroscience, 160 (2009), pp. 858-864
[9]
S. Dolgonos, H. Ayyala, C. Evinger.
Light-induced trigeminal sensitization without central visual pathways: another mechanism for photophobia.
Invest Ophthalmol Vis Sci, 52 (2011), pp. 7852-7858
[10]
H. Rossi, A. Recober.
Photophobia in primary headaches.
Headache, 55 (2015), pp. 600-604
[11]
T. Sprenger, P. Goadsby.
Migraine pathogenesis and state of pharmacological treatment options.
[12]
P. Gallin, M. Terman, C. Reme, B.T. Rafferty, R. Burde.
Ophtalmologic examination of patients with seasonal affective disorder, before and after bright light therapy.
Am J Ophtalmol, 119 (1995), pp. 202-210
[13]
L. Kelman, D. Tanis.
The relationship between migraine pain and other associated symptoms.
Cephalalgia, 26 (2006), pp. 548-553
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos